Media Articles Related to Zelnorm (Tegaserod)
IBS Pictures Slideshow: Understanding Irritable Bowel Syndrome
Source: MedicineNet Celiac Disease Specialty [2013.11.21]
Title: IBS Pictures Slideshow: Understanding Irritable Bowel Syndrome
Created: 2/12/2010 11:58:00 AM
Last Editorial Review: 11/21/2013 12:00:00 AM
UCLA researchers describe new form of irritable bowel syndrome
Source: Irritable-Bowel Syndrome News From Medical News Today [2013.09.09]
UCLA researchers have described a new form of irritable bowel syndrome (IBS) that occurs after an acute bout of diverticulitis, a finding that may help lead to better management of symptoms and relief for patients.
Studying The Causes Of Irritable Bowel Syndrome - GENIEUR
Source: Irritable-Bowel Syndrome News From Medical News Today [2013.02.06]
Experts and scientists from 19 European countries are getting together to investigate the causes of IBS (irritable bowel syndrome) with the aim of better understanding the condition and improving diagnosis and treatment.The team is led by researchers from the Sahlgrenska Academy, University of Gothenburg and Karolinska Institutet, both in Sweden.
Linaclotide Given Positive CHMP Opinion For Irritable Bowel Syndrome With Constipation
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.10.01]
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) have announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing approval for Constella® (linaclotide 290 micrograms), for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.
European Medicines Agency Recommends Authorisation Of First Medicine Specifically For Irritable Bowel Syndrome Constella
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.09.25]
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the authorisation of the first medicine specifically for the symptomatic treatment of irritable bowel syndrome (IBS) in the European Union (EU).
Published Studies Related to Zelnorm (Tegaserod)
Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia. [2011.02]
BACKGROUND: Abnormalities in gastric sensorimotor function (hypersensitivity to distention and impaired meal accommodation) have been implicated in the pathophysiology of functional dyspepsia (FD).In the subgroup with normal gastric emptying, tegaserod 6 mg b.i.d enhanced gastric accommodation.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. [2010.03]
BACKGROUND: Functional dyspepsia (FD) is a chronic disorder that adversely affects health-related quality of life (HRQoL). Published information on its long-term management is minimal and treatment options are limited. AIM: The aim of this study was to evaluate safety, efficacy and HRQoL with tegaserod 6 mg twice daily over 1 year in women with FD who completed one of two 6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was consistent with that of short-term treatment and accompanied by improvements in HRQoL, work productivity and symptom relief. These long-term results add to the clinical experience with FD and support the potential value of a 5-HT(4) agonist in the management of FD.
Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results
of two identical 1-year cohort studies. 
6-week, randomized, placebo-controlled, double-blind studies... CONCLUSIONS: The long-term safety profile of tegaserod in women with FD was
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. [2008.08]
BACKGROUND: Problems of compliance, quality, and safety of colon preparation regimens have prompted continued investigation with alternative forms of cleansing. OBJECTIVE: To evaluate the efficacy of tegaserod as an adjunct to a polyethylene glycol electrolyte solution (PEG-E), given as a whole dose or split dose, in colonoscopy preparation... CONCLUSIONS: Tegaserod has a marginal effect on the quality of colonoscopy preparation when used as an adjuvant to PEG-E. The split-dose PEG-E was superior to the whole-dose PEG-E and resulted in better colon cleansing, adherence, and tolerance.
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. [2008.08]
OBJECTIVES: Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD... CONCLUSIONS: Some improvement in dysmotility-like FD was observed with tegaserod treatment. The clinical implication of this improvement is uncertain.
Clinical Trials Related to Zelnorm (Tegaserod)
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation [No longer available]
To provide tegaserod to eligible women adult patients who did not have satisfactory
improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic
constipation (CIC) symptoms with other available treatment(s) and / or patients who had
satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis [Terminated]
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis
treated with tegaserod over 2 weeks.
Safety and Efficacy of Tegaserod in Opioid-Induced Constipation in Patients With Non-Cancer Pain. [Terminated]
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation
(OIC) in patients with non-cancer pain.
Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis (IA)
receive the treatment as follows:
Patients on tegaserod 6 mg twice daily (b. i.d.) or 12 mg once daily (o. d.) in the core study
will remain on the same dose in the extension (double-blind).
Patients on placebo during the core study will receive tegaserod 12 mg o. d. (open-label)
Patients who enter this study AFTER the core study interim analysis will receive the selected
tegaserod dose regimen (open-label) determined by the core study IA.
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. [Completed]
The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia [Withdrawn]
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in
female patients with CC and upper GI symptoms of dyspepsia